| Applications: |
WB |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
SARS CoV-2 Spike Glycoprotein South Africa variant Positive Control for STJ506303 is synthetically produced from the 400-450 sequence about the South Africa variant and is suitable for use in western blot applications. |
| Formulation: |
Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Immunogen Region: |
400-450 |
| Specificity: |
This is positive control is recommended for use in combination with SARS CoV-2 Spike Glycoprotein South Africa variant antibody STJ506303. |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
